Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sangamo Therapeutics Inc (NASDAQ:SGMO)

15.10
Delayed Data
As of Nov 21
 +0.40 / +2.72%
Today’s Change
2.65
Today|||52-Week Range
17.06
+395.08%
Year-to-Date
Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
Nov 16 / Zacks.com - Paid Partner Content
Gains Elude Market as Momentum Withers
Nov 15 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close14.70
Today’s open14.85
Day’s range14.75 - 15.50
Volume1,148,624
Average volume (3 months)1,556,384
Market cap$1.3B
Dividend yield--
Data as of 4:00pm ET, 11/21/2017

Growth & Valuation

Earnings growth (last year)-75.86%
Earnings growth (this year)+28.63%
Earnings growth (next 5 years)+24.50%
Revenue growth (last year)-50.96%
P/E ratioNM
Price/Sales11.10
Price/Book7.86

Competitors

----
EPZMEpizyme Inc+0.05+0.39%
FPRXFive Prime Therapeut...+0.67+2.55%
MNTAMomenta Pharmaceutic...+0.45+3.41%
Data as of 4:00pm ET, 11/21/2017

Financials

Next reporting dateFebruary 7, 2018
EPS forecast (this quarter)-$0.24
Annual revenue (last year)$19.4M
Annual profit (last year)-$71.7M
Net profit margin-369.58%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Alexander Macrae
Chief Financial Officer &
Senior Vice President
Kathy Yi
Corporate headquarters
Richmond, California

Forecasts